title: Microencapsulated mammalian cells for simultaneous production of VEGF165b and IFNα.
abstract: Targeted and simultaneous delivery VEGF165b and IFN alpha in anti-angiogenic and other applications could offer several advantages. For this a system was design using artificial cell alginate-poly-L-lysine- alginate (APA) microcapsules. Result confirms the ability of this system for simultaneous production of these proteins for 28-days. The IFN alpha on a 3 days period increased from 8 ± 0.36 μg/ml at day 10 to 27 ± 2.4 μg/ml at day 16 and then dropped to 6.5 ± 0.5 μg/ml. The VEGF165b on a 3 days period increased from 2.7 ± 0.7 μg/ml at day 10 to 6.9 ± 1 μg/ml at day 16.
authors.affiliation: Department of Biomedical Engineering and Artificial Cells and Organs Research Center, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Afkhami
authors.forename: Yves
authors.initials: Y
authors.lastname: Durocher
authors.forename: Satya
authors.initials: S
authors.lastname: Prakash
mesh_terms: D000464:Alginates / Q000737:chemistry; D058045:Artificial Cells / Q000166:cytology / Q000378:metabolism*; D002470:Cell Survival; D004339:Drug Compounding; D057809:HEK293 Cells; D006801:Humans; D016898:Interferon-alpha / Q000096:biosynthesis*; D011107:Polylysine / Q000031:analogs & derivatives / Q000737:chemistry; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis*
chemical_list: D000464:Alginates; D016898:Interferon-alpha; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C051546:alginate-polylysine-alginate; D011107:Polylysine